Neurofilament light as a translational biomarker from preclinical drug discovery to clinical application

insights from industryPhillip MitchellScience Director of Integrated BiologyCharles River Laboratories In this interview, industry expert Phillip Mitchell discusses the role of NfL biomarkers in CNS drug discovery, neurodegenerative disease research, treatment monitoring, neurotoxicity detection, and AI-driven biomarker selection. Can you tell us about your background and current role? My name is Phillip Mitchell, I am… Continue reading Neurofilament light as a translational biomarker from preclinical drug discovery to clinical application

In vitro and in vivo ADME of heterobifunctional degraders: a tailored approach to optimize DMPK properties of PROTACs©

Proteolysis-targeting chimeras (PROTACs©) have recently emerged as a promising new drug modality. Residing beyond the rule-of-five space, they pose challenges in terms of physicochemical properties. With this study, we contribute to enhancing the understanding of their early ADME characterization. For permeability assessment, transwell assays such as Caco-2 remain challenging. Although the addition of serum may… Continue reading In vitro and in vivo ADME of heterobifunctional degraders: a tailored approach to optimize DMPK properties of PROTACs©